- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03855111
Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Study Overview
Status
Conditions
Detailed Description
Distal sensory peripheral neuropathy (DSP) is a chronic, debilitating painful condition affecting quality of life in 20%-50% of persons living with HIV. Treatments prescribed to manage DSP pain, such as nonnarcotic and narcotic analgesics, antidepressants and anticonvulsants, are largely ineffective. Effective management of DSP pain is an unmet therapeutic need for this population. This study is a randomized, blinded, placebo-controlled clinical trial of the efficacy of Acupuncture/Moxibustion (Acu/Moxa) for HIV DSP pain/discomfort.
Subjects with HIV-related lower limb DSP pain are randomized to one of four Conditions: 1) Standard (fixed) protocol Acu/Moxa, 2) Individualized (tailored) protocol Acu/Moxa, 3) Sham Acu/Placebo Moxa (control), or 4) WaitList (control). Subjects attend six weeks of twice weekly treatment sessions and 3 non-treatment follow-up sessions at weeks 9, 11, and 15. All subjects are assessed by a blinded diagnostic acupuncturist (DA) and those assigned to Conditions 1, 2 and 3 receive treatments by an unblinded treating acupuncturist (TA). Specific Aims are: #1 determine group differences in weekly average pain (Gracely Pain Scale) at the end of treatment (Tx) and end of follow-up (F/U); SA#2 determine group differences in improvement in specific sensory symptoms (Subjective Peripheral Neuropathy Screen and neurological sensory testing (NST)) and patient-rated effectiveness (Clinical Global Improvement, NIH PROMIS Pain Intensity and Health-Related Quality of Life (MOS-HIV)) at Tx and F/U; SA#3 determine group differences in safety profiles; and SA#4, explore how baseline measures, TCM diagnoses, NST and pain medication use predict response to treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joyce K Anastasi, PhD
- Phone Number: 212-992-7044
- Email: joyce.anastasi@nyu.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10010
- Recruiting
- New York University, Division of Special Studies in Symptom Management
-
Contact:
- Ellie Gonzalez
- Phone Number: 212-992-5959
- Email: eg3400@nyu.edu
-
Principal Investigator:
- Joyce K Anastasi, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, 18 years of age or older, HIV+ or AIDS diagnosed, with a history of DSP of the lower extremities for the past three months or greater.
- Primary care provider (PCP) verification of HIV status, diagnosis of DSP, & subject clinical suitability for the study.
- Evidence of lower limb neuropathy (bilateral ankle reflexes absent or depressed relative to the knee, decreased sensation to vibration, pin prick and temperature with distal sensory loss grading to normal in the proximal limb)
- GPS rated pain severity of "moderate" or above, documented in 1-week prospective self-report symptom diary (SD).
- Any antiretroviral Rx must have 3 months of stable regimen (same drugs, dose & frequency) prior to enrollment.
- Any pain medications must have 3 months of stable regimen prior to enrollment.
- Those on a stable pharmacologic regimen are expected to remain on the regimen for the duration of the study.
- Must understand and agree to complete daily symptom diaries for the duration of the study.
- Successfully complete a mini-mental status exam (obtaining a score of 24 or above).
Exclusion Criteria:
- Any acute condition requiring medical care (eg. opportunistic infection).
- Conditions that may mimic HIV DSP symptoms: i.e. diabetes(3), coagulopathies, B12 deficiency, etc.
- Use any topically applied medications to the lower extremities.
- Alcohol and/or substance dependence.
- Use of injectable corticosteroids or any medications known to be neurotoxic within 3 months prior to enrollment.
- Pregnant women or unwilling to use an acceptable form of birth control.
- Receiving acupuncture within 6 months prior to enrollment.
- Any history of receiving moxibustion.
- Currently receiving any other complementary therapies such as herbs, massage, reiki etc.
- Relocation or plans that interfere with attending all of the planned study sessions and/or recording SD information.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Standard (fixed) protocol Acu/Moxa - Active
Standard (Fixed) Acupuncture / Moxibustion Active Protocol Subjects receive active standard Acu/Moxa protocol aimed at reducing neuropathic pain/discomfort. |
Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
Other Names:
|
Experimental: Individualized (tailored) protocol Acu/Moxa - Active
Individualized (Tailored) Active Acupuncture / Moxibustion Protocol Subjects receive active individualized Acu/Moxa protocol based on traditional Chinese medicine assessment aimed reducing neuropathic pain/discomfort. |
Individualized (tailored) protocol Acu/Moxa - Active.
Acu/Moxa prescription based on TCM assessment.
Protocol aimed at reducing lower limb neuropathic pain/discomfort.
Other Names:
|
No Intervention: Sham Acu/Placebo Moxa (Control)
Sham Acu/Placebo Moxa (Control) Note. All subjects randomized to the Control will be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation. |
|
No Intervention: WaitList (Control)
WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Acupuncture / Moxibustion. Note. All subjects randomized to the Control will then be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gracely Pain Scale (GPS)
Time Frame: Change from baseline rating of pain/discomfort (Gracely Pain Scale) after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine sustainability).
|
The GPS is a Likert magnitude-estimation log-scale of sensory pain. Subjects rate their DSP pain by selecting one of 13 words to describe their average and worst DSP pain. "Nothing"=0 to "Extremely intense"=12 |
Change from baseline rating of pain/discomfort (Gracely Pain Scale) after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine sustainability).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Peripheral Neuropathy Screen (SPNS)
Time Frame: Change from baseline rating of neuropathy symptoms after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Describes neuropathy symptoms eg.
aching/burning, "pins and needles", numbness, location (hands/arms, feet/legs), and severity of symptoms from "minimal" to "extreme".
|
Change from baseline rating of neuropathy symptoms after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
NIH PROMIS Pain Scale
Time Frame: Change from baseline rating of pain intensity after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity short form is used to assess "how much a person hurts".
Subjects in the last 7 days, the worst pain intensity, the average pain intensity.
Subjects rate their pain intensity from none (=1) to very severe (=5).
|
Change from baseline rating of pain intensity after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Medical Outcome Survey - HIV (MOS-HIV)
Time Frame: Change from baseline rating of general health after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
General health-related quality of life questions in HIV that assesses ten dimensions of health (overall health, pain, physical functioning, role and social functioning, mental health, energy/fatigue, cognitive function, health distress
|
Change from baseline rating of general health after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Clinical Global Severity Improvement Scale (CGIs)
Time Frame: Change from baseline rating of pain intensity after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
The severity of illness scale measures global severity of symptoms [in the context of peripheral neuropathy].
The patient rates discomfort from peripheral neuropathy on a scale of 0= No discomfort to 6= Very severe discomfort.
The global improvement component measures the level of change from initial severity: 0= No improvement at all to 6= Great improvement
|
Change from baseline rating of pain intensity after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Neurological Sensory Testing (NST)
Time Frame: Change from baseline neurological physical assessment after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Neurological assessments with Neuro Sensory Testing (NST) include: muscle strength and reflexes and sensory testing for lower limb vibration, pain and thermal sensation.
Standard neurological assessment: muscle strength 0-5; reflexes 0-5; pain- intact, reduced, absent, hyperalgesia; vibration - intact, impaired; thermal - intact, reduced absent.
The neuro/NST also serves to monitor for clinical safety and findings.
|
Change from baseline neurological physical assessment after 6 wks of twice-wkly treatment sessions (the end of the treatment phase) and at weeks 9, 11 and 15 (the follow-up phase - determine change and sustainability)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Slow Virus Diseases
- HIV Infections
- Neuralgia
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- S18-00257
- NIH-1R01NR017917-01 (Other Grant/Funding Number: National Institutes of Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Standard Acupuncture / Moxibustion
-
New York UniversityNational Institutes of Health (NIH)UnknownIrritable Bowel SyndromeUnited States
-
NYU Langone HealthColumbia UniversityCompletedHIV Infections | HIV | Peripheral Neuropathy | AIDSUnited States
-
National Center for Complementary and Integrative...CompletedHIV Infections | Peripheral NeuropathiesUnited States
-
Shanghai Institute of Acupuncture, Moxibustion...Changhai Hospital; Fudan University; Shanghai Jiao Tong University School of... and other collaboratorsCompleted
-
Shanghai Institute of Acupuncture, Moxibustion...Completed
-
Shanghai Institute of Acupuncture, Moxibustion...CompletedCrohn's Disease | CAMChina
-
The Third Affiliated hospital of Zhejiang Chinese...Recruiting
-
National Center for Complementary and Integrative...CompletedHIV InfectionsUnited States
-
Chang Gung Memorial HospitalRecruiting
-
Hubei Provincial Collaborative Innovation Center...Unknown